Abametapir
Brand names: Xeglyze · Active ingredient: Abametapir
In short: XEGLYZE is indicated for the topical treatment of head lice infestation in patients 6 months of age and older. XEGLYZE should be used in the context of an overall lice management program: Wash (with hot water) or dry-clean all recently worn clothing, hats, used bedding and towels Wash personal care
What is Abametapir used for?
XEGLYZE is indicated for the topical treatment of head lice infestation in patients 6 months of age and older.
XEGLYZE should be used in the context of an overall lice management program:
Wash (with hot water) or dry-clean all recently worn clothing, hats, used bedding and towels
Wash personal care items such as combs, brushes, and hair clips in hot water
Use a fine-tooth comb or special nit comb to remove dead lice and nits
Abametapir dosage
For topical use only. XEGLYZE is not for oral, ophthalmic, or intravaginal use. Treatment with XEGLYZE involves a single application.
Shake well before use. Apply XEGLYZE to dry hair in an amount (up to the full content of one bottle) sufficient to thoroughly coat the hair and scalp. Massage XEGLYZE into the scalp and throughout the hair. Avoid contact with eyes. Leave on the hair and scalp for 10 minutes and then rinse off with warm water. Wash hands after application. Hair may be shampooed any time after the treatment.
Discard any unused product. Do not flush contents down sink or toilet.
How to take Abametapir — instructions & advice from the label
Advise the patient or caregiver to read the FDA-approved patient labeling (Patient Information and Instructions for Use).
Inform the patient and caregiver of the following instructions:
Do not ingest XEGLYZE.
Keep out of reach of children. Use on children should be under the direct supervision of an adult because of the risk of benzyl alcohol toxicity .
Avoid contact with eyes.
Wash hands after application.
Hair may be shampooed any time after the treatment.
Treatment with XEGLYZE involves a single application. Do not re-treat.
Discard any unused portion. Do not flush contents down sink or toilet.
Manufactured by Groupe Parima Inc., for Dr. Reddy’s Laboratories, S.A. Elisabethenanlage 11, 4051 Basel, Switzerland
Distributed by Dr. Reddy’s Laboratories Inc., 107 College Road East, Princeton, NJ 08540
XeglyzeTM is a registered trademark of Dr. Reddy’s Laboratories, S.A.
Issued: 01 / 2022
Warnings & precautions
Do not take this medicine if: None.
XEGLYZE contains benzyl alcohol. Systemic exposure to benzyl alcohol has been associated with serious and fatal adverse reactions including “gasping syndrome” in neonates and low birth weight infants. The “gasping syndrome” is characterized by central nervous system depression, metabolic acidosis, and gasping respirations. The minimum amount of benzyl alcohol at which toxicity may occur is not known. Premature and low-birth weight infants may be more likely to develop toxicity .
The safety and effectiveness of XEGLYZE have not been established in pediatric patients below the age of 6 months. Use is not recommended in pediatric patients under 6 months of age because of the potential for increased systemic absorption.
In order to prevent accidental ingestion in pediatric patients, XEGLYZE should only be administered under direct supervision of an adult.
Ingestion of benzyl alcohol in large quantities may result in gastrointestinal (nausea, vomiting, diarrhea) and central nervous system (headache, ataxia, convulsions, coma) adverse reactions. Serious adverse reactions may include respiratory depression and death. If accidentally swallowed, advise the patient or the caregiver to call their Poison Control Center at 1-800-222-1222.
Abametapir side effects
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to the rates in the clinical trials of another drug, and may not reflect the rates observed in practice.
The data described below reflect exposure to a single 10-minute treatment of XEGLYZE in 349 subjects (6 months of age and older) with head lice infestation in randomized, double-blind, vehicle-controlled trials (Trials 1 and 2). Of these subjects, 21 were 6 months to 4 years of age, 166 subjects were 4 to 12 years of age, 57 subjects were 12 to 18 years of age, and 105 subjects were 18 years of age or older.
Table 1 provides adverse reactions that occurred in at least 1% of subjects in the XEGLYZE group and at a greater frequency than in the vehicle group.
Table 1: Adverse Reactions Occurring in ≥ 1% of the XEGLYZE Group and at a Greater Frequency than in the Vehicle Group (Trials 1 and 2)
Adverse Reactions | XEGLYZE N=349 Subjects (%) | Vehicle N=350 Subjects (%)
Erythema | 14 (4.0) | 6 (2)
Rash | 11 (3.2) | 8 (2.3)
Skin burning sensation | 9 (2.6) | 0 (0.0)
Contact dermatitis | 6 (1.7) | 4 (1.1)
Vomiting | 6 (1.7) | 2 (0.6)
Eye irritation | 4 (1.2) | 2 (0.6)
Hair color changes | 3 (1) | 0 (0.0)
During the trials, subjects were monitored for new onset of scalp erythema/edema, scalp pruritus, and eye irritation. …
Drug interactions
In vitro studies suggest there is a potential for inhibition of cytochrome P450 (CYP) 3A4, 2B6 and 1A2 enzymes following a single application of XEGLYZE. Use of XEGLYZE with drugs that are substrates of these enzymes may lead to increased systemic concentrations of the interacting drugs. Avoid administration of drugs that are substrates of CYP3A4, CYP2B6, or CYP1A2 within 2 weeks after application of XEGLYZE. If this is not feasible, avoid use of XEGLYZE .
About this medicine
The active pharmacological ingredient in XEGLYZE (abametapir) Lotion is the pediculicide, abametapir, which is a dipyridyl compound. The chemical name of abametapir is 5,5'-dimethyl-2,2'-bipyridinyl.
The structural formula is:
The empirical formula is C12H12N2 and the molecular weight is 184.24.
XEGLYZE is a white to off-white oil in water emulsion, containing 0.74% [weight by weight] of abametapir, intended for topical administration. XEGLYZE contains the following inactive ingredients: benzyl alcohol 2.0% , butylated hydroxytoluene, Carbomer Homopolymer Type C, light mineral oil, polysorbate 20, trolamine and water.
How it works: Abametapir (5,5’-dimethyl 2,2’-bipyridinyl) is a metalloproteinase inhibitor. Metalloproteinases have a role in physiological processes critical to egg development and survival of lice. Absorption The pharmacokinetics of XEGLYZE were evaluated in 3 trials, Trials A, B, and C.
Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID 4fe38e95-8738-a28f-4079-43eff7318cb9. Read the full official label on DailyMed.